Browsing by Author "Demir, Mehmet"
Now showing 1 - 7 of 7
- Results Per Page
- Sort Options
Publication Aviyonik ürün doğrulamasında titreşim fikstürü tasarımı(Bursa Uludağ Üniversitesi, 2023-10-23) Yıldırım, İbrahim; Meral, Ramazan; Güven, Caner; Çetin, Cansu Menşur; Demir, Mehmet; Çorbacı, Fikret KamilBu çalışma kapsamında, havacılık sektöründe kullanılan aviyonik bir ürün için, titreşim fikstürü tasarlanarak doğrulanmıştır. Sonlu elemanlar yöntemi kullanılarak modal analizler gerçekleştirilmiştir. Modal analizlerle tasarımı doğrulanan model, üretildikten sonra titreşim testlerine tabi tutulmuştur. Titreşim testleri esnasında ivmeölçerler yardımıyla veri toplanarak analiz sonuçları ile karşılaştırmalı olarak sunulmuştur. Korelasyonu sağlanan analiz ve test sonuçları ile titreşim fikstür tasarımının uygunluğu değerlendirilmiştir.Publication Demographic characteristics and transmission risk factors of patients with hepatitis c virus in Turkey: The EPI-C, a multicenter and cross-sectional trial(Galenos Yayıncılık, 2021-09-21) Tabak, Fehmi; Şirin, Göktuğ; Demir, Mehmet; Aladağ, Murat; Sümer, Sua; Kurtaran, Behice; Tosun, Selma; Yamazhan, Tansu; Bozkurt, İlkay; Gürbüz, Yunus; Batirel, Ayşe; Senateş, Ebubekir; Kandemir, Fatma Özlem; Topal, Firdevs; Doğanay, Hamdi Levent; Sezgin, Orhan; Mıstık, Reşit; Köse, Sükran; Yılmaz, Yusuf; İnan, Dilara; Köksal, İftihar; Parlak, Emine; Akdoğan, Meral; Güner, Rahmet; Mıstık, Reşit; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği.; 0000-0002-1548-8526; DFY-3761-2022Objectives: To describe the prevalence of risk factors in patients infected with hepatitis C virus (HCV).Materials and Methods: Patients who were aged >18 years visiting outpatient clinics and diagnosed as having HCV infection were enrolled in this cross-sectional, multicenter study conducted in 71 cities. Patient data on socio-demographic and clinical characteristics and pre-defined risk factors were collected.Results: Among 1,018 patients, 53.0% were women. The mean age was 57.2 +/- 14.3 years and 34.8% had been diagnosed as having HCV infection >10 years before enrollment. Almost half of the patients (45.5%) were diagnosed during their regular check-up visits, and only 16.8% were diagnosed because of signs or symptoms of HCV. Genotype 1 and sub-genotype 1 b were detected in 87.9% and 73.7% of the patients, respectively. At least one risk factor was present in 94.8% of the patients. The most frequently reported risk factor was major dental procedures (79.2%), followed by major surgical operations (56.9%) and minor surgical interventions (42.3%).Conclusion: Our results revealed that most of the patients with HCV infection underwent major dental procedures.Item Effect of the parity and the production year on the longevity of the kids in saneen dairy goats(Bursa Uludağ Üniversitesi, 2021-01-22) Çavuşoğlu, Enver; Riaz, Roshan; Omar, Mohamed Yusuf; Demir, Mehmet; Orman, Abdülkadir; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Hayvan Bilimleri Anabilim Dalı.; 0000-0002-9018-3511; 0000-0002-0524-9994; 0000-0002-5481-729X; 0000-0002-9279-3911; 0000-0001-9138-4422The basic objective of the dairy goat farmers is to produce healthy and fertile animals at appropriate age, with maximum genetic expression and long productive duration. Longevity is an important economical parameter in the breeding program of the dairy goats. There are various factors which directly influence the production and longevity of the newborns such as age at birth, season, herds flock and breed. The present study aimed to study the effect of the parity and the production year on the kids’ longevity in Saanen dairy goats. The 5 year data (2012 to 2016) of total 222 Saanen female goats collected from the Research and Applied Center at the Faculty of Veterinary Medicine, Bursa Uludag University. The effect of parity on the kids’ longevity was found non-significant (P>0.05). Non-significant (P>0.05) difference was observed while comparing the data of kids from primiparous and multiparous within the production year. However, a significant (P<0.05) difference among the mean values was found while making comparison between the production years. The litter size in the present study ranged from 1.57 to 1.75 and non-significant (P>0.05) difference was found in the kids born over the evaluated years. The present study did not investigate the voluntary and involuntary culling reasons and the management practices at the farm are more standardized than a normal commercial farm. Hence, further research is required at the commercial farms having large number of the animals and herds in order to use the parity and longevity in the present genetic evaluation programs.Publication Efficacy and safety of tenofovir alafenamide in hepatitis B virus-infected patients with chronic hemodialysis and renal transplantation: A preliminary result(Lippincott Williams & Wilkins, 2021-10-01) Adanır, Haydar; Etik, Diğdem Özer; Yıldırım, Abdullah Emre; Mehdiyev, Shahin; Yapalı, Suna; Coşar, Arif Mansur; Arı, Derya; Gökcan, Hale; Teker, Tufan; Kıyıcı, Murat; Balaban, Yasemin Hatice; Alkım, Hüseyin; Üçbilek, Enver; Ünsal, Yasemin; Harputluoğlu, Murat; Vatansever, Sezgin; Demir, Mehmet; Güzelbulut, Fatih; Gündüz, Feyza; Boyacıoğlu, Sedat; Bilgiç, Yılmaz; Ekmen, Nergis; Arslan, Mehmet; Şimşek, Halis; Akdoğan, Meral; Dinçer, Dinç; Tozun, Nurdan; İdilman, Ramazan; TEKER, TUFAN; KIYICI, MURAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; EAB-6931-2022; FHW-0015-2022Publication Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort(Wiley, 2019-06-01) İdilman, Ramazan; Demir, Mehmet; Aladağ, Murat; Erol, Cihan; Çavuş, Bilger; İliaz, Raim; Köklü, Hayrettin; Çakaloğlu, Yılmaz; Şahin, Memduh; Ersöz, Galip; Köksal, İftihar; Karasu, Zeki; Özgenel, Meriç; Turan, İlker; Gündüz, Feyza; Ataseven, Hüseyin; Akdoğan, Meral; Kıyıcı, Murat; Köksal, Aydın Şeref; Akhan, Sila; Günsar, Fülya; Tabak, Fehmi; Kaymakoglu, Sabahattin; Akarca, Ulus S.; Akarsu, Mesut; Alkim, Hüseyin; Araz, Filiz; Ateş, Fehmi; Aygen, Bilgehan; Balık, İsmail; Barut, Hüseyin S.; Baysal, Birol; Bolat, Aylin; Çelik, İlhami; Coşgun, Süleyman; Ensaroglu, Fatih; Gökcan, Hale; Gürel, Selim; Gürsoy, Şebnem; İnkaya, Ahmet Çağan; Kamilli, Cemil; Kav, Taylan; Kuruüzüm, Ziya; Önder, Fatih O.; Örmeci, Necati; Özbakır, Ömer; Özenirler, Seren; Özer, Birol; Özkan, Hasan; Poturoğlu, Şule; Senates, Ebubekir; Şimşek, Halis; Toka, Bilal; Ünal, Hakan; Yaras, Serkan; Yıldırım, Abdullah E.; Yıldırım, Beytullah; Yılmaz, Bülent; Yılmaz, Hasan; Yozgat, Ahmet; Yurdaydın, Cihan; Early Access Program EAP Study Grp; KIYICI, MURAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı; 0000-0002-3208-6211; AAI-4213-2021The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma.Publication Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience(Aves, 2020-10-09) Değertekin, Bülent; Demir, Mehmet; Akarca, Ulus S.; Kani, Haluk Tarık; Üçbilek, Enver; Yıldırım, Emre; Güzelbulut, Fatih; Balkan, Ayhan; Vatansever, Sezgin; Danış, Nilay; Demircan, Melek; Soylu, Aliye; Yaras, Serkan; Kartal, Aysun; Kefeli, Ayşe; Gündüz, Feyza; Yalçın, Kendal; Erarslan, Elife; Aladağ, Murat; Harputluoğlu, Murat; Özakyol, Ayşegül; Temel, Tuncer; Akarsu, Mesut; Sümer, Hale; Akın, Mete; Albayrak, Bülent; Şen, İlker; Alkim, Hüseyin; Uyanıkoğlu, Ahmet; Irak, Kader; Öztaşkın, Sinem; Uğurlu, Çağrı Burak; Güneş, Şevkican; Gürel, Selim; Nuriyev, Kenan; İnci, İsmail; Kaçar, Sabite; Dinçer, Dinç; Doğanay, Levent; Göktürk, Hüseyin Savaş; Mert, Ali; Coşar, Arif Mansur; Dursun, Hakan; Atalay, Roni; Akbulut, Sabiye; Balkan, Yasemin; Koklu, Hayrettin; Şimşek, Halis; Özdoğan, Osman; Çoban, Mehmet; Poturoğlu, Şule; Ayyıldız, Talat; Yapalı, Suna; Günşar, Fulya; Akdoğan, Meral; Özenirler, Seren; Akyıldız, Murat; Sezgin, Orhan; Özdoğan, Osman; Kaymakoğlu, Sabahattin; Besişik, Fatih; Karasu, Zeki; Idılman, Ramazan; GÜREL, SELİM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji ve Hepatoloji Anabilim Dalı.; 0000-0002-7279-2161; HLH-8209-2023Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.Material and Methods: A total of 4,352 patients with CHC from 36 different institutions in Turkey were enrolled. They received ledipasvir (LDV) and sofosbuvir (SOF)+/- ribavirin (RBV) ombitasvir/paritaprevir/ritonavir +/- dasabuvir (PrOD)+/- RBV for 12 or 24 weeks. Sustained virologic response (SVR) rates, factors affecting SVR, safety profile, and hepatocellular cancer (HCC) occurrence were analyzed.Results: SVR12 was achieved in 92.8% of the patients (4,040/4,352) according to intention-to-treat and in 98.3% of the patients (4,040/4,108) according to per-protocol analysis. The SVR12 rates were similar between the treatment regimens (97.2%-100%) and genotypes (95.6%-100%). Patients achieving SVR showed a significant decrease in the mean serum alanine transaminase (ALT) levels (50.90 +/- 54.60 U/L to 17.00 +/- 14.50 U/L) and model for end-stage liver disease (MELD) scores (7.51 +/- 4.54 to 7.32 +/- 3.40) (p<0.05). Of the patients, 2 were diagnosed with HCC during the treatment and 14 were diagnosed with HCC 37.0 +/- 16.0 weeks post-treatment. Higher initial MELD score (odds ratio [OR]: 1.92, 95% confidence interval [CI]: 1.22-2.38; p=0.023]), higher hepatitis C virus (HCV) RNA levels (OR: 1.44, 95% CI: 1.31-2.28; p=0.038), and higher serum ALT levels (OR: 1.38, 95% CI: 1.21-1.83; p=0.042) were associated with poor SVR12. The most common adverse events were fatigue (12.6%), pruritis (7.3%), increased serum ALT (4.7%) and bilirubin (3.8%) levels, and anemia (3.1%).Conclusion: LDV/SOF or PrOD +/- RBV were effective and tolerable treatments for patients with CHC and with or without advanced liver disease before and after liver transplantation. Although HCV eradication improves the liver function, there is a risk of developing HCC.Item Recurrence and occurrence of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment for chronic hepatitis C in patients with advanced liver disease: Turkish multi-center early access program(Elsevier, 2018-04) İdilman, Ramazan; Demir, Mehmet; Aladağ, Murat; Kaymakoğlu, Sabahattin; Erol, Cihan; Çavuş, Bilger; İliaz, Raim; Akarca, Ulus S.; Köklü, Seyfettin; Çakaloğlu, Yılmaz; Şahin, M.; Köksal, I.; Özgenel, Meriç; Toka, Bilal; Karasu, Zeki; Ersöz, Galip; Akdoğan, Meral; Kıyıcı, Murat; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; AAI-4213-2021